Bioxytran Inc (QB) (BIXT) Quote

Where do you do your DD dude? The library of the Roman Empire or the Middle ages?|

More Hogwash and fairy tails just like you did on IFUS, before you got schooled and educated by me?

https://www.slideserve.com/cana/avraham-mayevsky

"MDX Viewer as an analytical method, which is an FDA approved device to measure tissue oxygenation. The device measures the consumption of oxygen molecules in tissues on a cellular level.

The output of the MDX Viewer is the Brain Metabolic Score BMS, which is a vital part of the approval process for Bioxytran’s acellular oxygen carrier (AOC) molecule called BXT-25. Bioxytran plans on using the BXT-25 in its clinical trials for ischemic stroke and Alzheimer’s disease patients as a way to replace hyperbaric oxygen treatment (HBOT).

https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html

The device is already FDA Approved:

"The book is directly tied to the Hypoxia platform technology which uses the MDX Viewer as an analytical method, which is an FDA approved device to measure tissue oxygenation. "

You said: He is head of MDX Life Sciences which has developed the MDX Viewer and is seeking FDA approval for the device. You shouldn't spread misinformation.

I read that she won a Nobel prize already
Are you talking about Avraham Mayevsky? The advisor is a "he" not a "she" and "he" didn't win a Nobel prize. He is head of MDX Life Sciences which has developed the MDX Viewer and is seeking FDA approval for the device. You shouldn't spread misinformation.

BTW, David Platt (CEO of BIXT) and Ola Soderquist (CFO of BIXT) are also managers in MDX Life Sciences. You can find info on the company at MDX Life Sciences. The MDX Viewer is being used to validate BXT-25 and neither of these products have FDA approval. I'm not sure how useful the MDX Viewer and associated TMS score are and also am not clear on the relationship between BIXT and MDX Life Sciences. The MDX Viewer and BXT-25 seem to be tightly linked - they might both be revolutionary products or could both end up in the ashbin of history. I hope it is the former.

Nice rally today up 9.65% on slow pre Holiday day

I noticed a 1/2 Million share bid show up this week and the well known naked shorts/MMs backed up in a panic looking for cloths and fresh shelter. It was rather comical.

Reminded me of

You still panhandle bashing for the paychecks at the Hedge fund/Broker dealer, trying to manipulate the stock price for chump change?

Do not forget, I read that she won a Nobel Prize already

$BIXT News June 27, 2024

Bioxytran’s Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer’s Patients
https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html

The CEO has been running around for years telling the same BS story. Ask him how last company did?

If there’s any chance on earth that this medical technology can do anything on that scale even close isn’t it a gift from heaven?

Nobody noticed.

This is very promising and exciting for the company and shareholders

https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html

$BIXT News June 27, 2024

Bioxytran’s Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer’s Patients
https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html

do you not have anything better to do then try and bad mouth ecomike all over ihub.
I have made more money thanks to ecomike then from anyone else.

So much potential and so little progress. They have been talking about performing a dosing study for over a year now and still don't seem to have started. And the dosing study is required before they can even begin Phase III testing. What the heck is going on? They set up their Indian subsidiary at the end of 2022 for commercialization and they still seem to be sitting on their hands, waiting for what?

The latest news is painting a bleak picture for the future of COVID... experts predict that, with repeated COVID infections, everyone will eventually be suffering from long COVID. BIXT has a solution but doesn't seem to feel any urgency.

Sounds like a dud. PPS remains depressed

**BIXT Live chat starts in 15 minutes**

MIAMI , June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024.
The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.
Register for the Conference here.
https://goto.webcasts.com/starthere.jsp?ei=1658205&tp_key=76d4029138&sti=globe
Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com

**BIXT is at 1:10 PM today (I think EST zone since the conference firm is in Florida?)**

What would you like to know about BIXT?

Just read an article about this : anybody have any real
Insight about the actual company ?

Just read an article about this : anybody have any real
Insight about the actual company ?

100% go look at RVVTF which he pumped incessantly as it tanked

If EGOmike is pumping you better be dumping.

No one has pumped on more no bid stocks than the Ego.

Please read and share this

https://medicaldialogues.in/medicine/news/galectin-3-promising-biomarker-for-predicting-long-covid-among-patients-of-covid-19-study-129158

Yes I believe you are correct

Share this good news with everyone you know!

https://www.insiderfinancial.com/post/playing-the-bird-flu-trade-cvac-bixt-nnvc-govx-dyai-nvax

The first description of avian influenza (AI) dates back to 1878 in northern Italy, when Perroncito [Perroncito E. Epizoozia tifoide nei gallinacei. Annali Accad Agri Torino 1878;21:87-126] described a contagious disease of poultry associated with high mortality.

The vaccine wasn't created for the bird flu...The bird flu was created for the vaccine. So let's keep everyone sick. After all, from Merck's point of view, heal a patient\lose a customer...The disease management system we're saddled with has made the United States' pharmaceutical labyrinth the laughing stock of the civilized world during the past forty years. Pity...

The vaccine wasn't created for the bird flu; the bird flu was created for the vaccine....Heal a patient, lose a customer...I think that pretty much explains what's wrong with the disease management system that's made the U.S. the laughing stock of the civilized world during the past 40 years...

BIXT CTB Cost To Borrow is already over 78% annual interest rate, up over 30000% above normal.

Shorts on BIXT got played..

Folks you have a choice. Bill Gate's Death by clot shot, if the Bird Flu vaccine or enhanced, Added gain of function, new improved bird flu, Bird flu a la Bill Gates research lab leaks the newer more dangerous bird flu they created for vaccine research....

Or BIXT, who has a published patent covering/targeting the galectin fold of 60+ viruses including bird flu and RSV, HIV, Epstein Barr's trigger MS, and Covid(all strains) and long haul covid19 with a non toxic oral pill, that has zero side effects?

Hard choice I know...

Is Big Pharma afraid of losing trillions of dollars of sales when BIXT gets approved and succeeds? 100% paranoid yes. So much so they have shorted the hell out of BIXT...

This is us, verses Big Pharama and their investors now

They will loose...

https://childrenshealthdefense.org/defender/united-states-bankrolling-creation-deadlier-contagious-bird-flu-strains/?utm_source=luminate&utm_medium=email&utm_campaign=defender&utm_id=20240520

YES!!!!

Dumb Money's (The Movie) Game Stop savior ROARING-KITTY that Bankrupted Ken Griffins 6.8 billions dollar hedge fund in 2021 is back today, after an 18 month break.
That stock and Amc rallied biggly today, So maybe we recuit them to get eyes on BIXT?

I agree that the National Institutes of Health and\or the US Military would be very useful collaborators in any attempt to establish a viable market for BIXT's biotech...But would either of them be willing to take a flier on a bulletin board company with no revenues? I certainly hope so, but...

Why not work with NIH?

It is indeed an ethical (and a preemptive) project that should be undertaken by anyone interested in avoiding the pain and extraordinary expense of current medical treatments typically prescribed for the very conditions Bioxytran appears equipped to address...That expressed, I'm nervous that Bioxytran may remain on the sidelines indefinitely unless the right kind (and number) of private (and retail) investors come forward to invest.

As always, we'll see...
C

That is why I call BIXT an ethical Investment in our health, that we the people need to fight for.

It should have occurred to me that entrenched sector giants like Merck or J & J would prefer to squelch competition in the interest of ramping up profits, and would rather see BIXT remain an obscure, off-the-radar OTC company that can never threaten market share currently monoploized by the behemoths...Sigh...

Todays emerging growth conference
CEO DAVID PLATT $BIXT
BioxyTran.

https://emerginggrowth.com/emerging-growth-conference-70/

Looks likes BIXT is the perfect remedy for a biological warfare just drop one of those pills

Only two problems, that will be solved. One is Hedge fund mugllers doing what they do. In our case handing us truck loads of gift priced shares from dumb (hedge fund) money.

The bigger they are, the harder they fall.

The other problem is that Big drug firms depend on lifelong sick people for their profits. They have no interesting in funding tech that will gut Cancer, and chronic autoimmune disease drug sales, that big pharma makes crime level profits off of.

This is where retail and ethical investors like us need to wake up and fund it, move it to warp speed, as fast as possible, because the health of friends and family and fellow humans now and in the future need it badly, asap.

It puzzles and dismays me that a patient-friendly non injectable remedy for common metabolic disorders hasn't yet attracted funding or transformed Bioxytran into a viable takeover target by, say, Merck, Monsanto or J&J, et al...I'm long on BIXT and will empty the bank for it if other stocks I'm waiting on come through in a timely manner...

$BIXT News analyst paper
https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22

For those in a rush, slow readers, skip down the bottom for $BIXT connect the dots, connection.

Investing requires leading with an edge and some forethought. This article highlights pure-play drug developers in MASH likely to be the focus of investors looking for the next big thing in biotech.

Looking Beyond GLP-1 Inhibitors Toward the MASH Epidemic

Drug makers like Eli Lilly (NYSE: LLY) with their drug Mounjaro (tirzepatide) have already repurposed their drug once and are looking beyond diabetes and obesity, with their eyes set on and an even more lucrative market of metabolic dysfunction-associated steatohepatitis (MASH). LLY has promising interim clinical data showing 74% of overweight adults who took the higher dose of tirzepatide cleared MASH versus 12.6% in placebo. The first approval of a MASH drug on March 15, 2024 by Madrigal Pharmaceuticals (NASDAQ: MDGL) has ignited the sector with investors looking for the next big pure play.

Multiple MASH Targets

Metabolic dysfunction-associated steatohepatitis (MASH) is a complicated disease on the regulatory front. Approval criteria are a resolution of MASH symptoms via biopsy without a worsening of fibrosis. The disease formerly known as nonalcoholic steatohepatitis (NASH) is caused by a buildup of fat in the liver that leads to complications which include fibrosis (scarring of the liver), cirrhosis (severe scarring of the liver), and liver cancer. Once MASH progresses this far, liver transplantation is currently the only viable option. After MDGL’s approval of Rezdiffera®, investors have been flocking to other MASH names looking for a follow-on drug that either works in combination with Rezdiffera or one that is superior in safety and efficacy.

MASH Drug Targets

MASH has several druggable targets. The GLP-1 target is the mainstream approach because it also treats type 2 diabetes. Next in terms of a drug target is the fibroblast growth factor 21 (FGF21) which has a number of players in late-stage development. Galectin-3 is another target for MASH drugs as research has shown it is implicated in fibrotic and inflammatory feedback loops. There are also promising drugs that target the thyroid hormone receptor beta (THRß). Breaking from the mainstream approaches is the A3 adenosine receptor (A3AR) which is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells.

FGF21 Agonists

89Bio Inc. (NASDAQ: ETNB) is developing a lead molecule called pegozafermin which is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It is similar in mechanism of action to Bristol Myers Squibb’s (NYSE: BMY) drug pegbelfermin which was discontinued despite positive results which showed more than half the patients having NASH resolution at 16 weeks. FGF21 analogues are taken via subcutaneous injection. The targeting of the FGF21 pathway helps regulate metabolism and cellular process, especially in the liver fat tissue. Balancing out this metabolic pathway helps reduce liver fat, which can result in reduction in liver fibrosis (scarring) over time. The company has strong fibrosis data with favorable tolerability and dosing convenience. The long term data suggests there is a cumulative impact on patients taking background GLP-1 therapy. ETNB’s phase 3 program in MASH could achieve accelerated approval using histology in non-cirrhotic (F2-F3) and cirrhotic (F4) patients although the FDA has acknowledged greater importance in clinical outcomes and not histology. They have clinical trials in both fibrosis and cirrhosis and expect to initiate their cirrhosis trial in Q2 2024. The company has almost $600 million in cash with a market cap of $875 million. The slight premium over cash, solid and consistent trial results, along with short and long-term catalysts make this an attractive setup for investors. This is the first on the top 6 list.

Akero Therapeutics (NASDAQ: AKRO) is also targeting MASH and MASH cirrhosis with an FGF21 agonist. Their drug is called efruxifermin and is commonly referred to as EFX. In their phase 2b MASH trial they showed a 65% reduction in liver fat content vs 11% in placebo which places them close to the front of the pack because it was done in only 12 weeks. Unfortunately, their phase 2b trial in MASH missed the endpoint for improvement in liver fibrosis at the 12-week time frame but showed 60% had MASH resolution after 36 weeks versus 26% in placebo. The company lost a lot of value on that readout but the statistics show a cleanly designed trial is likely to hit the regulatory endpoints. Guidance from an end-of-trial FDA meeting is forthcoming, but the timing is still uncertain and weighing on the stock price. While there is a lot of potential in this name, the uncertain timing of the regulatory pathway makes this ideal for the patient investor looking more for a NASH cirrhosis play. The company is well funded with over $550 million in cash and a $1.5 billion market cap.

Galectin-3 Antagonists

Galectin Therapeutics (NASDAQ: GALT) has an adaptive design phase 2/3 study in NASH cirrhosis with an interim readout before year end 2024. Their intravenously administered galectin antagonist called belapectin showed complete prevention of esophageal varices in a phase 2 trial despite failing to meet their (now defunct) primary endpoints. Their pivotal trial used lessons learned from the phase 2 trial, utilizing a primary endpoint of prevention of esophageal varices. If the interim results confirm a complete or near complete prevention of varices like they did in their phase 2 trial, they would have a compelling argument for conditional approval, likely with another post-market confirmatory phase 3 trial. Almost 50% of patients that develop esophageal varices die within a year, and the varices are extremely costly to treat. So eliminating the significant and imminent threat of death is the compelling benefit.

The company is in solid financial shape with enough cash runway to complete their pivotal trial by 2025. They also have the backing of a billionaire investor who is also their Chairman of the Board. Additionally, their drug demonstrated promising results in cancer, psoriasis, and atopic dermatitis which could lead to a label expansion once they are approved. The market cap of the company is sitting around $225 million despite the near certainty of a positive interim trial readout within the next 8 months, which could translate into billions within that time frame.

The company is not alone in the space and has 2 other competitors with oral galectin-3 antagonists. Galecto Bioscience (NASDAQ: GLTO) announced they were scrapping their cancer drug, which had a 60% response rate after three months, to focus on NASH. GLTO had a failed trial in idiopathic pulmonary fibrosis because of their drug’s poor tolerability, which has forced them to seek strategic alternatives with a focus on liver disease. As a result, their development timelines for MASH are in flux. Galecto’s small molecule approach to inhibiting intracellular galectin-3 is the likely culprit for their drug’s poor tolerability and its more likely large molecules which target extracellular galectin-3 will succeed.

Bioxytran Inc. (OTCMKTS: BIXT) has the most technologically advanced oral galectin antagonist that completed phase 2 trials in standard risk COVID-19, but the company is underfunded and therefore moving forward cautiously. Both Bioxytran and Galectin Therapeutics are developing larger molecules compared with Galecto and both their drugs have been found to be safe as opposed to Galecto. Bioxytran’s additional benefit is that their drug doesn’t require intravenous administration. Their clinical trials in NASH or cancer are dependent upon them finding a partner or a couple million dollars to get a shot at a number of multibillion dollar opportunities. Management indicated that the quickest way to approval was a COVID-19 regulatory approval and then proceeding with the label expansion. While the company boasts impressive technology and experienced management, they don’t have the resources to prove their technology for all these indications yet. It's for these reasons that the stock should remain high on peoples watch lists—in case they get funding.

See the article for the rest of the story

Please read this.

https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22

Great Idea........one day $BIXT will be famous for curing these viruses..........

Z

This situation with the emerging Bird Flu epidemic is reminiscent of the Mad Cow disaster which was triggered by feeding bovines ground up cattle meat and bone meal containing self-propagating prions--just as God intended, eh?

What if $BIXT 's antiviral is used with Ifus cattle feed to stop bird flu?

https://www.telegraph.co.uk/global-health/science-and-disease/chicken-waste-fed-to-cattle-may-be-behind-bird-flu-outbreak/
The Telegraph
Ground-up chicken waste fed to cattle may be behind bird flu outbre...
Experts warn that lax regulations could also see the virus spread to US pig farms, with serious consequences for human health

[10:36 PM]
Fears are growing that the H5N1 outbreak among cattle in the United States could have been caused by contaminated animal feed.

In contrast to Britain and Europe, American farmers are still allowed to feed cattle and other farm animals ground-up waste from other animals including birds.

Dairy cows across six US states – and at least one farm worker – have become infected with the highly pathogenic virus, which has already killed millions of animals across the globe since 2021.

The farm worker, who is thought to have been exposed via infected cattle in Texas, is only the second recorded human H5N1 case in the US. Since February, the US has investigated and discounted a further 8,000 possible exposures, according to Dr Joshua Mott, WHO senior advisor on influenza.

The development is of concern because it allows the virus, which has killed millions of birds and wild mammals around the world, more opportunities to mutate.
[10:39 PM]
Experts fear that H5N1, which was only first detected in cows a few weeks ago, may have been transmitted through a type of cattle feed called “poultry litter” – a mix of poultry excreta, spilled feed, feathers, and other waste scraped from the floors of industrial chicken and turkey production plants.

In the UK and EU, feeding cows proteins from other animals has been tightly regulated since the outbreak of BSE – or ‘mad cow disease’ – 30 years ago.

Experts are unsure but fear it could be the poultry litter feed used in the US that has passed the virus to cattle.

“In the US, the feeding of poultry litter to beef cows is a known factor in the cause of botulism in cattle, and is a risk in the case of H5N1,” said Dr Steve Van Winden, Associate Professor in Population Medicine at the Royal Veterinary College.

Dr Tom Peacock, a virologist and fellow at the Pirbright Institute agreed: “This latest case wouldn’t be the first time there have been concerns H5N1 could be moving through different mammals via contaminated feed,” citing the outbreak of avian flu in cats in Poland last year, which experts suspected might have been transmitted through mink byproducts used in raw cat food.

The US cattle industry is worth over $100 billion and regulations covering animal standards there have long been controversial in Europe – most famously over the use of hormones in the rearing of cattle for meat.
[10:40 PM]
Although the presence of H5N1 in US cattle herds increases the risk of the virus getting into humans via farm workers, it is the spread of the virus to pig farms that presents the bigger threat.

This is because pigs have receptors on some cells that are similar to humans, making it much more likely that the virus could mutate and jump to humans if pig farms become infected.

So far, the virus hasn’t shown any signs of worrying mutation, however.

“Infection of H5N1 in pigs is of particular concern – they are highly susceptible to human influenza virus strains so could act as mixing vessels for avian and human viruses to mix and generate viruses that can more efficiently infect humans,” said Dr Tom Peacock.

Poultry litter is not only cheaper than other food sources like soy and grains but is also more calorie-dense, meaning farmers can bulk up their herds much more quickly.

https://www.insiderfinancial.com/post/galectin-therapeutics-galt-a-discount-opportunity-moving-on-analysts-upgrade

Great read. I bought some galt today as well.